Tim Smith

In this analysis, investigators looked at quality of life data among pediatric patients with atopic dermatitis in Sub-Saharan Africa.

In this analysis, evidence which supports a shift in clinical practice using Chinese herbal medicine was explored for atopic dermatitis.

This study highlights an approach to male pattern baldness using a topical dimethylglycine sodium salt (DMG-Na) and caffeine-containing shampoo.

This cohort study suggests that patients with HS treated with adalimumab have an increased risk of infection compared to those with psoriasis.

A study reveals that upadacitinib dose adjustments in atopic dermatitis enhance treatment personalization.

In this analysis, investigators looked into age-stratified impacts of rivaroxaban as a monotherapy versus the impacts of rivaroxaban plus antiplatelet agent combination treatment.

This study suggests a causative role of left bundle branch block (LBBB) in patients’ progression to heart failure.

This analysis of patients with atopic dermatitis in the BIOREP registry spotlight the safety and efficacy of lebrikizumab therapy.

This analysis suggests that GLP-1 RAs provide promise for those with HS and obesity and potentially for such individuals without obesity via immunological impacts.

The G-EPOSS study demonstrated the long-term impacts of guselkumab on patients’ psoriasis symptoms, sexual impairment, and perceived stigmatization.

This August 2025 News Update spotlights Ugonabo’s career journey, her award and its story, and the growing importance of tailored dermatologic care for diverse skin tones.

This systematic review and meta-analysis found that biologic switching was shown to be safe and effective among patients with psoriasis.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

This summary of dermatology news coverage from the month of August 2025 highlights some of the most notable stories in this medical subfield.

These data from the ICONIC-LEAD study were presented at DERM 2025, highlighting the efficacy and safety of icotrokinra in patients with psoriasis.

In this summary of coverage at the DERM 2025 conference, a list of notable stories highlighting acne management strategies is highlighted.

In this list of the top 5 posters featured at the DERM 2025 conference, a variety of recent data are spotlighted in alopecia areata, atopic dermatitis, and other disease states.

News coverage from DERM 2025 in the field of psoriasis is highlighted in this post-conference summary.

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

This list highlights a variety of notable DERM 2025 conference news coverage, specifically in the field of atopic dermatitis.

The PAISLEY CLE trial findings highlight deucravacitinib’s efficacy among patients with cutaneous lupus, including those with concurrent SLE.

These data were presented at DERM 2025, highlighting recent findings on the impact of tralokinumab on atopic dermatitis.

These pooled THRIVE-AA1 and THRIVE-AA2 study data highlight improvements in mental health among patients with alopecia given deuruxolitinib.

This session was titled ‘The Hidden Undercurrent: When Hair Loss Isn’t Alopecia Areata’ and was presented at the DERM 2025 conference by April Armstrong, MD, MPH.

This interim data was drawn from the TRACE study, highlighting real-world use of tralokinumab in adults with atopic dermatitis of the head and neck.

In an ADvocate study subpopulation, new findings suggest lebrikizumab therapy leads to significant disease control and positive itch impacts.

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

This interview segment highlights additional information on the 16-week risankizumab data from the phase 4 UnlIMMited study.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.

This interview with Song at DERM2025 highlights recent phase 3 data on risankizumab for genital and scalp psoriasis.